Levent KILIÇ, Emre BİLGİN, Ali AKDOĞAN, Umut KALYONCU, Sedat KİRAZ, Ömer KARADAĞ, Ali İhsan ERTENLİ, Gözde Kübra YARDIMCI, Emine DURAN, , Ertuğrul Çağrı BÖLEK, Furkan CEYLAN, Bayram FARİSOĞULLARI, Şule Apraş BİLGEN

Efficacy, retention, and safety of tofacitinib in real-life: Hur-bio monocentric experience

Background/aim: To assess the real-life efficacy, retention rate, and safety data of tofacitinib in rheumatoid arthritis (RA) patients. Materials and methods: We analyzed all patients registered in the HURBİO database who received at least 1 dose of tofacitinib. Patients who received at least one dose were included in retention analysis; patients with at least 1 control visit were included in efficacy and safety analysis. Factors predicting good response at the last follow-up visit were analyzed by logistic regression analysis. Drug retention rates were calculated using the Kaplan–Meier method and predictors of drug retention were determined by Cox proportional hazard model. Adverse events, reasons for switching, and discontinuation were also determined. Results: Two hundred and forty-seven (210, 85.0% female) patients were included in the study. The median duration of tofacitinib treatment was 10.2 (20.2) [med, (IQR)] months. Two hundred and four (82.6%) patients were included in safety and efficacy analysis; 45.6% of patients were in low-disease activity (LDA) state (DAS28-CRP ≤ 3.2). Predictors of LDA were being biologic-naïve [aOR 2.53 (1.31–4.88); 95% CI] and RF negativity [aOR 2.14 (1.12–4.07); 95% CI]. At 1 year, the overall tofacitinib retention rate was 63.9% with no relevant predicting factor. Response and retention rates of tofacitinib were similar in patients with and without concomitant csDMARDs. Treatment failure was the most common cause of discontinuation. The most common infectious and laboratory adverse events were herpes zoster infection (3.9 per 100 patient-years) and elevation in ALT (x3UNL: 9.7 per 100 patient-years), respectively. Conclusion: Tofacitinib is effective as monotherapy or in combination with csDMARDs. It is a well-tolerated treatment option in Turkish RA patients.Key words: Rheumatoid arthritis, tofacitinib, real-life, predictor

PDF

___

1. Aletaha D, Smolen JS. Diagnosis and management of rheumatoid arthritis: a review. JAMA 2018; 320 (13): 1360- 1372. doi: 10.1001/jama.2018.13103
2. Smolen JS, Landewe RBM, Bijlsma JWJ, Burmester GR, Dougados M et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Annals of the Rheumatic Diseases 2020; 79 (6): 685- 699. doi: 10.1136/annrheumdis-2019-216655
3. Keystone EC, Kavanaugh AF, Sharp JT, Tannenbaum H, Hua Y et al. (2004) Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis and Rheumatology 2004; 50 (5): 1400-1411. doi: 10.1002/art.20217
4. Burmester GR, Blanco R, Charles-Schoeman C, Wollenhaupt J, Zerbini C et al. Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial. Lancet 2013; 381 (9865): 451-460. doi: 10.1016/S0140-6736(12)61424-X
5. Fleischmann R, Kremer J, Cush J, Schulze-Koops H, Connell CA et al. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. New England Journal of Medicine 2012; 367 (6): 495-507. doi:10.1056/NEJMoa1109071
6. Kremer J, Li ZG, Hall S, Fleischmann R, Genovese M et al. Tofacitinib in combination with nonbiologic diseasemodifying antirheumatic drugs in patients with active rheumatoid arthritis: a randomized trial. Annals of Internal Medicine 2013; 159 (4): 253-261. doi:10.7326/0003-4819-159- 4-201308200-00006
7. Tanaka Y, Suzuki M, Nakamura H, Toyoizumi S, Zwillich SH et al. Phase II study of tofacitinib (CP-690,550) combined with methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate. Arthritis Care Research (Hoboken) 2011; 63 (8): 1150-1158. doi: 10.1002/acr.20494
8. Van Vollenhoven RF, Fleischmann R, Cohen S, Lee EB, Garcia Meijide JA et al. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. New England Journal of Medicine 2012; 367 (6): 508-519. doi: 10.1056/NEJMoa1112072
9. Vieira MC, Zwillich SH, Jansen JP, Smiechowski B, Spurden D et al. Tofacitinib versus biologic treatments in patients with active rheumatoid arthritis who have had an inadequate response to tumor necrosis factor inhibitors: results from a network meta-analysis. Clinical Therapy 2016; 38 (12): 2628- 2641.e5. doi: 10.1016/j.clinthera.2016.11.004
10. Fleischmann R, Mysler E, Hall S, Kivitz AJ, Moots RJ et al. Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial. Lancet 2017; 390 (10093): 457-468. doi: 10.1016/S0140- 6736(17)31618-5
11. Nikiphorou E, Buch MH, Hyrich KL. Biologics registers in RA: methodological aspects, current role and future applications. Nature Reviews Rheumatology 2017; 13 (8): 503-510. doi: 10.1038/nrrheum.2017.81
12. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis and Rheumatology 1988; 31 (3): 315-324. doi: 10.1002/ art.1780310302
13. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis and Rheumatology 2010; 62 (9): 2569-2581. doi: 10.1002/art.27584
14. Prevoo ML, Van ‘t Hof MA, Kuper HH, van Leeuwen MA, Van de Putte LB et al. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis and Rheumatology 1995; 38 (1): 44-48. doi: 10.1002/art.1780380107
15. Van Gestel AM, Prevoo ML, Van ‘t Hof MA, Van Rijswijk MH, Van de Putte LB et al. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria. Arthritis and Rheumatology 1996; 39 (1): 34-40. doi: 10.1002/art.1780390105
16. Wells GA, Tugwell P, Kraag GR, Baker PR, Groh J et al. Minimum important difference between patients with rheumatoid arthritis: the patient’s perspective. Journal of Rheumatology 1993; 20 (3): 557-560.
17. Fries JF, Spitz P, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. Arthritis and Rheumatology 1980; 23 (2): 137-145. doi: 10.1002/art.1780230202
18. Wollenhaupt J, Silverfield J, Lee EB, Curtis JR, Wood SP et al. Safety and efficacy of tofacitinib, an oral janus kinase inhibitor, for the treatment of rheumatoid arthritis in open-label, longterm extension studies. Journal of Rheumatology 2014; 41 (5): 837-852. doi: 10.3899/jrheum.130683
19. Iwamoto N, Tsuji S, Takatani A, Shimizu T, Fukui S et al. Efficacy and safety at 24 weeks of daily clinical use of tofacitinib in patients with rheumatoid arthritis. PLoS One 2017; 12 (5): e0177057. doi: 10.1371/journal.pone.0177057
20. Lee EB, Fleischmann R, Hall S, Wilkinson B, Bradley JD et al. Tofacitinib versus methotrexate in rheumatoid arthritis. New England Journal of Medicine 2014; 370 (25): 2377-2386. doi: 10.1056/NEJMoa1310476
21. Wollenhaupt J, Lee EB, Curtis JR, Silverfield J, Terry K et al. Safety and efficacy of tofacitinib for up to 9.5 years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study. Arthritis Research and Therapy 2019; 21 (1): 89-107. doi: 10.1186/s13075-019-1866-2
22. Mueller RB, Hasler C, Popp F, Mattow F, Durmisi M et al. Effectiveness, tolerability, and safety of tofacitinib in rheumatoid arthritis: a retrospective analysis of real-world data from the St. Gallen and Aarau cohorts. Journal of Clinical Medicine 2019; 8 (10): 1548-1562. doi: 10.3390/jcm8101548
23. Kyburz D, Riek M, Herzog L. Use of tofacitinib in rheumatoid arthritis: data from the Swiss clinical quality management RA registry. Arthritis and Rheumatology 2016; 68 (S10): Abstract 1637.
24. Schneeberger EE, Salas A, LF M. Real-world use of tofacitinib in rheumatoid arthritis: data from Latin America. Annals of the Rheumatic Diseases 2017; 76 (Suppl. 29): 196.
25. Fickh A, Herzog L, Scherer A, Dudler J, Moeller B. THU0174 Drug retention of tofacitinib versus biologic antirheumatic agents in rheumatoid arthritis: observational data from the Swiss SCQM registry. Annals of the Rheumatic Diseases 2017; 76 (Suppl. 2): 267.
26. Mori S, Yoshitama T, Ueki Y. Tofacitinib therapy for rheumatoid arthritis: a direct comparison study between biologic-naive and experienced patients. Internal Medicine 2018; 57 (5): 663- 670. doi: 10.2169/internalmedicine.9341-17
27. Bird P, Hall S, Nash P, Connell CA, Kwok K et al. Treatment outcomes in patients with seropositive versus seronegative rheumatoid arthritis in Phase III randomised clinical trials of tofacitinib. RMD Open 2019; 5 (1): e000742. doi: 10.1136/ rmdopen-2018-000742
28. Miriovsky BJ, Michaud K, Thiele GM, O’Dell JR, Cannon GW et al. Anti-CCP antibody and rheumatoid factor concentrations predict greater disease activity in men with rheumatoid arthritis. Annals of the Rheumatic Diseases 2010; 69 (7): 1292- 1297. doi: 10.1136/ard.2009.122739
29. Lv Q, Yin Y, Li X, Shan G, Wu X et al. The status of rheumatoid factor and anti-cyclic citrullinated peptide antibody are not associated with the effect of anti-TNFalpha agent treatment in patients with rheumatoid arthritis: a meta-analysis. PLoS One 2014; 9(2): e89442. doi: 10.1371/journal.pone.0089442
30. Aletaha D, Alasti F, Smolen JS. Rheumatoid factor, not antibodies against citrullinated proteins, is associated with baseline disease activity in rheumatoid arthritis clinical trials. Arthritis Research Therapy 2015; 17(1): 229-239. doi: 10.1186/ s13075-015-0736-9
31. Santos-Moreno P, Sanchez G, Castro C. Rheumatoid factor as predictor of response to treatment with anti-TNF alpha drugs in patients with rheumatoid arthritis: results of a cohort study. Medicine (Baltimore) 2019; 98 (5): e14181. doi: 10.1097/ MD.0000000000014181
32. Takeuchi T, Miyasaka N, Inui T, Yano T, Yoshinari T et al. High titers of both rheumatoid factor and anti-CCP antibodies at baseline in patients with rheumatoid arthritis are associated with increased circulating baseline TNF level, low drug levels, and reduced clinical responses: a post hoc analysis of the RISING study. Arthritis Research and Therapy 2017; 19 (1): 194-205. doi: 10.1186/s13075-017-1401-2
33. Soubrier M, Pereira B, Frayssac T, Fan A, Couderc M et al. Retention rates of adalimumab, etanercept and infliximab as first-line biotherapy agent for rheumatoid arthritis patients in daily practice - Auvergne experience. International Journal of Rheumatic Diseases 2018; 21 (11): 1924-1932. doi: 10.1111/1756-185X.13156
34. Croiteru A, Lidar M, Reitblat T. Real-life retention of tofacitinib in patients with rheumatoid arthritis. Arthritis and Rheumatology 2019; (Suppl 10): 71.
35. Kobayakawa T, Kojima T, Takahashi N, Hayashi M, Yabe Y et al. Drug retention rates of second biologic agents after switching from tumor necrosis factor inhibitors for rheumatoid arthritis in Japanese patients on low-dose methotrexate or without methotrexate. Modern Rheumatology 2015; 25 (2): 251-256. doi: 10.3109/14397595.2014.953668
36. Bergrath E, Gerber RA, Gruben D, Lukic T, Makin C et al. Tofacitinib versus biologic treatments in moderate-to-severe rheumatoid arthritis patients who have had an inadequate response to nonbiologic dmards: systematic literature review and network meta-analysis. International Journal of Rheumatol 2017; e8417249. doi: 10.1155/2017/8417249
37. Singh JA, Hossain A, Tanjong Ghogomu E, Mudano AS, Maxwell LJ et al. Biologics or tofacitinib for people with rheumatoid arthritis unsuccessfully treated with biologics: a systematic review and network meta-analysis. Cochrane Database Systematic Reviews 2017; 3: CD012591. doi: 10.1002/14651858.CD012591
38. Zhang Z, Deng W, Wu Q, Sun L. Tuberculosis, hepatitis B and herpes zoster in tofacitinib-treated patients with rheumatoid arthritis. Immunotherapy 2019; 11 (4): 321-333. doi: 10.2217/ imt-2018-0113
39. Bechman K, Subesinghe S, Norton S, Atzeni F, Galli M et al. A systematic review and meta-analysis of infection risk with small molecule JAK inhibitors in rheumatoid arthritis. Rheumatology (Oxford) 2019; 58 (10): 1755-1766. doi: 10.1093/rheumatology/kez087
40. Winthrop KL, Curtis JR, Lindsey S, Tanaka Y, Yamaoka K et al. Herpes zoster and tofacitinib: clinical outcomes and the risk of concomitant therapy. Arthritis and Rheumatology 2017; 69 (10): 1960-1968. doi: 10.1002/art.40189